SPOTLIGHT: Encysive losses mount

Encysive losses mount
Shares of Encysive Pharmaceuticals took a hit in premarket trading after the company announced bigger losses than the numbers predicted by analysts. Much of the red ink was spilled in preparing for the European launch of its hypertension drug Thelin. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.